Stefano Canosa, Alberto Revelli, Gianluca Gennarelli, Gennaro Cormio, Vera Loizzi, Francesca Arezzo, Easter Anna Petracca, Andrea Roberto Carosso, Danilo Cimadomo, Laura Rienzi, Alberto Vaiarelli, Filippo Maria Ubaldi and Erica Silvestris
Healthcare 2023, 11, 2748. https:// doi.org/10.3390/healthcare11202748 Submission received: 22 August 2023 / Revised: 5 October 2023 / Accepted: 12 October 2023 / Published: 17 October 2023
Abstract
Recent advances in anticancer treatment have significantly improved the survival rate of young females; unfortunately, in about one third of cancer survivors the risk of ovarian insufficiency and infertility is still quite relevant. As the possibility of becoming a mother after recovery from a juvenile cancer is an important part of the quality of life, several procedures to preserve fertility have been developed: ovarian surgical transposition, induction of ovarian quiescence by gonadotropin-releasing hormone agonists (GnRH-a) treatment, and oocyte and/or ovarian cortical tissue cryopreservation. Ovarian tissue cryostorage and allografting is a valuable technique that applies even to prepubertal girls; however, some patients cannot benefit from it due to the high risk of reintroducing cancer cells during allograft in cases of ovary-metastasizing neoplasias, such as leukemias or NH lymphomas. Innovative techniques are now under investigation, as in the construction of an artificial ovary made of isolated follicles inserted into an artificial matrix scaffold, and the use of stem cells, including ovarian stem cells (OSCs), to obtain neo-folliculogenesis and the development of fertilizable oocytes from the exhausted ovarian tissue. This review synthesizes and discusses these innovative techniques, which potentially represent interesting strategies in oncofertility programs and a new hope for young female cancer survivors.
Keywords: cryopreservation; fertility preservation; oncofertility; cancer survivor; artificial ovary; stem cells